Core Insights - Garden Bio reported a slight decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] - The company experienced a significant drop in both revenue and net profit in the third quarter of 2025 [1] Financial Performance - For the first three quarters of 2025, Garden Bio achieved operating revenue of 936 million yuan, a year-on-year decrease of 0.2% [1] - The net profit attributable to shareholders for the same period was 234 million yuan, down 3.07% year-on-year [1] - In the third quarter of 2025, the company reported operating revenue of 300 million yuan, reflecting a year-on-year decline of 10.99% [1] - The net profit for the third quarter was 72.51 million yuan, which represents a year-on-year decrease of 27.02% [1]

Core Insights - Garden Biologics (300401) reported a decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved a revenue of 300 million yuan in Q3, representing a year-on-year decrease of 10.99% [1] - The net profit attributable to shareholders for Q3 was 72.51 million yuan, down 27.02% year-on-year [1] - For the first three quarters, the net profit attributable to shareholders totaled 234 million yuan, reflecting a year-on-year decline of 3.07% [1]

Core Viewpoint - Garden Biologics reported a slight decline in revenue and net profit for the third quarter of 2023, indicating potential challenges in maintaining growth in a competitive market [1] Financial Performance - Revenue for the first three quarters of 2025 was approximately 936 million yuan, a year-on-year decrease of 0.2% [1] - Net profit attributable to shareholders was around 234 million yuan, reflecting a year-on-year decline of 3.07% [1] - Basic earnings per share were 0.43 yuan, down 4.44% compared to the previous year [1]

Core Insights - Garden Biotech reported Q3 2025 revenue of 300 million, a year-on-year decrease of 10.99% [1] - Net profit for Q3 2025 was 72.51 million, down 27.02% year-on-year [1] - For the first three quarters of 2025, revenue totaled 936 million, reflecting a slight year-on-year decline of 0.20% [1] - Net profit for the first three quarters was 234 million, showing a year-on-year decrease of 3.07% [1]

智通财经APP讯，花园生物(300401.SZ)发布2025年三季度报告，该公司前三季度营业收入为9.36亿元， 同比减少0.20%。归属于上市公司股东的净利润为2.34亿元，同比减少3.07%。归属于上市公司股东的扣 除非经常性损益的净利润为2.21亿元，同比增长9.06%。基本每股收益为0.43元。 ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating potential challenges in its financial performance [1] Financial Performance Summary - The company's revenue for the third quarter was 300 million, a year-on-year decrease of 10.99% [1] - The net profit for the third quarter was 72.51 million, reflecting a year-on-year decline of 27.02% [1] - For the first three quarters, the total revenue was 936 million, showing a slight year-on-year decrease of 0.20% [1] - The net profit for the first three quarters was 234 million, which represents a year-on-year decline of 3.07% [1]

花园生物公告，第三季度营收为3亿元，同比下降10.99%；净利润为7251.23万元，同比下降27.02%。前 三季度营收为9.36亿元，同比下降0.20%；净利润为2.34亿元，同比下降3.07%。 ...

Core Viewpoint - Garden Biologics (300401.SZ) reported a slight decline in revenue and net profit for the first three quarters of the year, while showing growth in net profit excluding non-recurring items [1] Financial Performance - The company's operating revenue for the first three quarters reached 936 million yuan, representing a year-on-year decrease of 0.20% [1] - The net profit attributable to shareholders was 234 million yuan, down 3.07% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 221 million yuan, reflecting a year-on-year increase of 9.06% [1]

浙江花园生物医药股份有限公司 2025 年第三季度报告 | | | 浙江花园生物医药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 浙江花园生物医药股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 300,340,615.92 | -10.99% | 935,701,786.71 | -0.20% | | ...

（文章来源：证券日报） 证券日报网讯花园生物10月15日在互动平台回答投资者提问时表示，截至2025年10月10日，公司股东总 户数为28，597户。 ...